Snowden Capital Advisors’s Teva Pharmaceuticals TEVA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $664K | Buy |
39,593
+3,710
| +10% | +$62.2K | 0.02% | 655 |
|
|
2025
Q1 | $552K | Buy |
35,883
+3,320
| +10% | +$51K | 0.02% | 698 |
|
|
2024
Q4 | $718K | Sell |
32,563
-4,350
| -12% | -$95.9K | 0.02% | 624 |
|
|
2024
Q3 | $665K | Buy |
36,913
+5,285
| +17% | +$95.2K | 0.02% | 647 |
|
|
2024
Q2 | $514K | Sell |
31,628
-1,568
| -5% | -$25.5K | 0.02% | 737 |
|
|
2024
Q1 | $468K | Buy |
33,196
+4,124
| +14% | +$58.2K | 0.01% | 788 |
|
|
2023
Q4 | $304K | Buy |
29,072
+129
| +0.4% | +$1.35K | 0.01% | 900 |
|
|
2023
Q3 | $295K | Buy |
28,943
+18,587
| +179% | +$190K | 0.01% | 866 |
|
|
2023
Q2 | $78K | Buy |
+10,356
| New | +$78K | ﹤0.01% | 1147 |
|
|
2022
Q1 | – | Sell |
-41
| Closed | – | – | 1965 |
|
|
2021
Q4 | $0 | Buy |
+41
| New | – | ﹤0.01% | 2153 |
|